Subcutaneous (SubQ) injection is the most common administration route for research peptides. Done correctly, it's straightforward — a short needle, a small volume, injected into fatty tissue just under the skin. Done incorrectly, it causes unnecessary pain, bruising, and inconsistent absorption. This guide covers everything: needle selection, injection sites, technique, and troubleshooting.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
28–31 gauge is standard. 29G is the most common choice — thin enough to cause minimal pain, thick enough that drawing from a vial doesn't take forever. 31G is the thinnest commonly available and is virtually painless but draws slower.
What SubQ Injection Actually Does
Subcutaneous tissue sits just below the dermis and above the muscle layer. It's well-vascularised with a relatively slow but consistent blood supply, which means peptides injected here are absorbed gradually into systemic circulation rather than in a rapid bolus. For most peptides — including BPC-157, TB-500, GHK-Cu, and GH secretagogues — this slow absorption is actually desirable, producing a sustained plasma concentration rather than a sharp spike.
The SubQ layer is also largely free of major blood vessels and nerves, making it significantly more forgiving than intramuscular injection for a first-time injector. The standard needle length for SubQ is 5/16 inch (8mm) or 1/2 inch (12.7mm), 28–31 gauge. Most peptide researchers use 29G or 31G half-inch insulin syringes.
Common Injection Sites
The abdomen is the most commonly used SubQ injection site — specifically the area 2 inches to either side of the navel. Abdominal SubQ tissue is thick, accessible, and absorbs well. It's also easy to self-administer.
Other viable sites include: the outer thigh (lateral quadriceps region), the lateral upper arm, and the lower back / flank area. Rotating between sites prevents lipohypertrophy (fatty lumps that can develop from repeated injection at the same spot) and maintains consistent absorption.
Sites to avoid: directly over the navel, directly over veins or arteries (look before injecting), areas with active bruising or infection, and the inner thigh where skin is thin and movement causes friction.
Step-by-Step Injection Protocol
| Step | Action | Notes |
|---|---|---|
| 1 | Wash hands thoroughly | 30 seconds, soap and water |
| 2 | Wipe injection site with alcohol swab | Let dry 30 seconds — wet alcohol stings |
| 3 | Pinch skin between thumb and forefinger | Creates a fold of SubQ tissue |
| 4 | Insert needle at 45° angle (or 90° for longer needles) | 45° for thin individuals, 90° for thicker SubQ |
| 5 | Inject slowly — 10 seconds for 0.1 mL | Slow injection reduces pressure and pain |
| 6 | Withdraw needle at same angle as entry | Don't twist or drag |
| 7 | Apply light pressure with swab | Do not rub — spreads the injection |
Troubleshooting Common Issues
**Bleeding after injection:** Usually a minor capillary nick. Apply light pressure for 30 seconds. Normal and not a concern unless it doesn't stop.
**Pain or burning during injection:** Usually caused by alcohol that hasn't fully dried, injecting too fast, or a bent needle tip (always use fresh needles). Cold peptide solution can also cause brief discomfort — let the syringe warm to room temperature.
**Raised lump after injection:** Normal. A small bleb of fluid under the skin will absorb within 15–30 minutes. Rubbing it doesn't help and may cause bruising.
**Bruising:** Common, especially in abdominal site. Usually from minor vessel contact. Rotate sites to allow recovery. Not dangerous.
**Air bubbles in syringe:** Tap the syringe gently and push the plunger slightly to expel. In SubQ injections, small bubbles are not dangerous (unlike IV injection), but good practice to remove them.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
28–31 gauge is standard. 29G is the most common choice — thin enough to cause minimal pain, thick enough that drawing from a vial doesn't take forever. 31G is the thinnest commonly available and is virtually painless but draws slower. Avoid anything below 28G for SubQ — unnecessary pain and tissue trauma.
SubQ injections target the fatty tissue directly under the skin, roughly 4–8mm deep depending on body composition. A 5/16 inch (8mm) needle inserted at 45° reaches the SubQ layer on most people. Thinner individuals may prefer a shallower angle; more substantial SubQ tissue allows 90° insertion.
Not recommended. Repeated injection at the same site causes lipohypertrophy — hardened fatty lumps that reduce absorption consistency. Rotate between at least 3–4 sites. Mark a rotation schedule if you're injecting multiple times daily.
No. Aspiration (pulling back the plunger to check for blood before injecting) is no longer recommended for SubQ injections and was never necessary for IM injections at most sites. Major blood vessels don't run through typical SubQ injection sites. Current best practice is to skip aspiration for SubQ.
SubQ goes into fatty tissue just below the skin (slower absorption, more consistent plasma levels). IM goes directly into muscle tissue (faster absorption, sharper peak). Most peptide protocols use SubQ. IM is sometimes used for TB-500 loading doses or when faster systemic absorption is specifically desired. SubQ is lower risk and appropriate for most peptide research protocols.
Generally yes, if both are reconstituted in BAC water and neither is known to be chemically incompatible with the other. BPC-157 and TB-500 are commonly injected together. CJC-1295 and Ipamorelin are routinely combined. Mixing should be done immediately before injection, not stored pre-mixed. When in doubt, use separate syringes.